La economía del bien común.

The Common Good economy is a new economic model, proposed by Christian Felber in the year 2012. It is a new way of understanding the economy; taking into consideration social and human values. The following project aims to show a global vision of this theory, comparing it with ancient economic theories and, subsequently, to make known the impact it has had on the world and on our environment. With the balance and the matrix of the common good will check how the behaviour of enterprises is measured in this new model. This paper seeks to make known the novelty of the model, as well as the great impact it would have on the environment and in social inequalities.La economía del Bien Común es un nuevo modelo económico, propuesto por Christian Felber en el año 2010. Se trata de una nueva forma de entender la economía, tomando en consideración valores sociales y humanos. El siguiente trabajo pretende mostrar una visión global de esta teoría, comparándola con teorías económicas antiguas para, posteriormente, dar a conocer el impacto que ha tenido en el mundo y en nuestro entorno. Con el balance y la matriz del bien común se comprobará la forma en que se mide el comportamiento de las empresas en esta nueva propuesta. Con este trabajo se intenta dar a conocer lo novedoso del modelo, así como el gran impacto que tendría en el medioambiente y en las desigualdades sociales

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio